Are we missing the mTOR target in breast cancer?
Johnston
Stephen R D
SR
Royal Marsden Hospital, Chelsea, London, SW3 6JJ, UK. stephen.johnston@rmh.nhs.uk
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D000068338:Everolimus; D005260:Female; D006801:Humans; D038762:Ribosomal Protein S6 Kinases, 70-kDa / Q000378:metabolism*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism*
D000970:Antineoplastic Agents; D000068338:Everolimus; D038762:Ribosomal Protein S6 Kinases, 70-kDa; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus